Tags

Type your tag names separated by a space and hit enter

Childhood Atopic Dermatitis Impact Scale: reliability, discriminative and concurrent validity, and responsiveness.
Arch Dermatol 2007; 143(6):768-72AD

Abstract

OBJECTIVE

To evaluate the test-retest reliability, discriminative and concurrent validity, and responsiveness of the Childhood Atopic Dermatitis Impact Scale (CADIS), a quality-of-life scale with 5 domains.

DESIGN

Prospective, longitudinal study.

SETTING

Two academic pediatric dermatology practices.

PATIENTS

A total of 301 parents of children younger than 6 years with atopic dermatitis.

MAIN OUTCOME MEASURES

Participants completed the CADIS, sociodemographic items, and other clinical questions at enrollment and at a 4-week follow-up. In addition, 41 participants completed the CADIS again 48 hours after baseline. Disease severity was measured using the Severity Scoring of Atopic Dermatitis (SCORAD) index for all children.

RESULTS

Of 301 enrolled participants, 270 (90%) completed the enrollment materials and 228 (84%) of these completed the 4-week follow-up materials. Thirty-four (83%) of the 41 participants completed the 48-hour materials. Intraclass correlation coefficients of CADIS scores at enrollment and at 48 hours ranged from 0.89 to 0.95. Correlations between CADIS scores and the SCORAD index scores (range, 0.42-0.72) demonstrated that more severe atopic dermatitis is associated with worse quality of life. Scores from all 5 domains of the CADIS significantly differentiated patients at each severity level as measured by the SCORAD index (P<.001). Participants who rated their children as "improved" at the 4-week follow-up had significantly better CADIS scores than those who rated their children as having the "same" or "worse" skin disease (P<.05).

CONCLUSIONS

These data confirm the test-retest reliability, concurrent validity, and discriminative validity of the CADIS. In addition, responsiveness evaluation demonstrates that the CADIS accurately measures change in patients whose disease improves.

Authors+Show Affiliations

Division of Pediatric Dermatology, Children's Memorial Hospital, Chicago, IL 60614, and Center on Outcomes Research and Education, Evanston Northwestern Healthcare and Northwestern Feinberg School of Medicine, USA. schamlin@childrensmemorial.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Studies

Language

eng

PubMed ID

17576944

Citation

Chamlin, Sarah L., et al. "Childhood Atopic Dermatitis Impact Scale: Reliability, Discriminative and Concurrent Validity, and Responsiveness." Archives of Dermatology, vol. 143, no. 6, 2007, pp. 768-72.
Chamlin SL, Lai JS, Cella D, et al. Childhood Atopic Dermatitis Impact Scale: reliability, discriminative and concurrent validity, and responsiveness. Arch Dermatol. 2007;143(6):768-72.
Chamlin, S. L., Lai, J. S., Cella, D., Frieden, I. J., Williams, M. L., Mancini, A. J., & Chren, M. M. (2007). Childhood Atopic Dermatitis Impact Scale: reliability, discriminative and concurrent validity, and responsiveness. Archives of Dermatology, 143(6), pp. 768-72.
Chamlin SL, et al. Childhood Atopic Dermatitis Impact Scale: Reliability, Discriminative and Concurrent Validity, and Responsiveness. Arch Dermatol. 2007;143(6):768-72. PubMed PMID: 17576944.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Childhood Atopic Dermatitis Impact Scale: reliability, discriminative and concurrent validity, and responsiveness. AU - Chamlin,Sarah L, AU - Lai,Jin-Shei, AU - Cella,David, AU - Frieden,Ilona J, AU - Williams,Mary L, AU - Mancini,Anthony J, AU - Chren,Mary-Margaret, PY - 2007/6/20/pubmed PY - 2007/7/27/medline PY - 2007/6/20/entrez SP - 768 EP - 72 JF - Archives of dermatology JO - Arch Dermatol VL - 143 IS - 6 N2 - OBJECTIVE: To evaluate the test-retest reliability, discriminative and concurrent validity, and responsiveness of the Childhood Atopic Dermatitis Impact Scale (CADIS), a quality-of-life scale with 5 domains. DESIGN: Prospective, longitudinal study. SETTING: Two academic pediatric dermatology practices. PATIENTS: A total of 301 parents of children younger than 6 years with atopic dermatitis. MAIN OUTCOME MEASURES: Participants completed the CADIS, sociodemographic items, and other clinical questions at enrollment and at a 4-week follow-up. In addition, 41 participants completed the CADIS again 48 hours after baseline. Disease severity was measured using the Severity Scoring of Atopic Dermatitis (SCORAD) index for all children. RESULTS: Of 301 enrolled participants, 270 (90%) completed the enrollment materials and 228 (84%) of these completed the 4-week follow-up materials. Thirty-four (83%) of the 41 participants completed the 48-hour materials. Intraclass correlation coefficients of CADIS scores at enrollment and at 48 hours ranged from 0.89 to 0.95. Correlations between CADIS scores and the SCORAD index scores (range, 0.42-0.72) demonstrated that more severe atopic dermatitis is associated with worse quality of life. Scores from all 5 domains of the CADIS significantly differentiated patients at each severity level as measured by the SCORAD index (P<.001). Participants who rated their children as "improved" at the 4-week follow-up had significantly better CADIS scores than those who rated their children as having the "same" or "worse" skin disease (P<.05). CONCLUSIONS: These data confirm the test-retest reliability, concurrent validity, and discriminative validity of the CADIS. In addition, responsiveness evaluation demonstrates that the CADIS accurately measures change in patients whose disease improves. SN - 0003-987X UR - https://www.unboundmedicine.com/medline/citation/17576944/Childhood_Atopic_Dermatitis_Impact_Scale:_reliability_discriminative_and_concurrent_validity_and_responsiveness_ L2 - https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/archderm.143.6.768 DB - PRIME DP - Unbound Medicine ER -